OTCPK:EQUR

Stock Analysis Report

Executive Summary

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • E-Qure has significant price volatility in the past 3 months.
  • E-Qure is not covered by any analysts.

Share Price & News

How has E-Qure's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:EQUR

2.9%

US Medical Equipment

2.9%

US Market


1 Year Return

-13.6%

OTCPK:EQUR

14.0%

US Medical Equipment

0.2%

US Market

EQUR underperformed the Medical Equipment industry which returned 14% over the past year.

EQUR underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

EQURIndustryMarket
7 Day0%2.9%2.9%
30 Day-21.3%0.8%-2.3%
90 Dayn/a11.3%3.1%
1 Year-13.6%-13.6%14.9%14.0%2.4%0.2%
3 Year-65.0%-65.0%71.4%66.1%41.7%32.4%
5 Year-98.3%-98.3%134.0%107.1%55.1%37.9%

Price Volatility Vs. Market

How volatile is E-Qure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is E-Qure undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether E-Qure is trading at an attractive price based on the cash flow it is expected to produce in the future. But as E-Qure has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of EQUR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through E-Qure regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is E-Qure expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as E-Qure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of EQUR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access E-Qure's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has E-Qure performed over the past 5 years?

71.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

E-Qure does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare E-Qure's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare E-Qure's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if E-Qure has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if E-Qure has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if E-Qure improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is E-Qure's financial position?


Financial Position Analysis

E-Qure's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

E-Qure has no long term commitments.


Debt to Equity History and Analysis

E-Qure has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if E-Qure's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

E-Qure has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

E-Qure has less than a year of cash runway based on current free cash flow.

E-Qure has less than a year of cash runway if free cash flow continues to grow at historical rates of 45.7% each year.


Next Steps

Dividend

What is E-Qure's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate E-Qure's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate E-Qure's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as E-Qure has not reported any payouts.

Unable to verify if E-Qure's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as E-Qure has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of E-Qure's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Ohad Goren (48yo)

5.2yrs

Tenure

0

Mr. Ohad Goren has been the Chief Executive Officer of E-Qure Corp. since June 2014 and its Director since July 25, 2018. Mr. Goren has been an Advisor and Entrepreneur to Medical Device companies since 20 ...


CEO Compensation Analysis

Ohad's remuneration is lower than average for companies of similar size in United States of America.

Ohad's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.2yrs

Average Tenure

48yo

Average Age

The average tenure for the E-Qure management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

3.0yrs

Average Tenure

60yo

Average Age

The tenure for the E-Qure board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Itsik Ben Yesha (66yo)

    CTO & Director

    • Tenure: 1.1yrs
    • Compensation: US$72.50k
  • Ohad Goren (48yo)

    CEO & Director

    • Tenure: 5.2yrs
  • Gal Peleg (41yo)

    Chief Financial Officer

    • Tenure: 5.0yrs
  • Itai Weisberg

    Chief Marketing Consultant

    • Tenure: 6.1yrs

Board Members

  • Ben-Zion Weiner (75yo)

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Itsik Ben Yesha (66yo)

    CTO & Director

    • Tenure: 1.1yrs
    • Compensation: US$72.50k
  • Michael Sessler (60yo)

    Director

    • Tenure: 5.0yrs
  • Ohad Goren (48yo)

    CEO & Director

    • Tenure: 5.2yrs
  • Avi Ohry

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Ron Weissberg (60yo)

    Chairman

    • Tenure: 5.7yrs

Company Information

E-Qure Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: E-Qure Corp.
  • Ticker: EQUR
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.418m
  • Shares outstanding: 34.55m
  • Website: https://www.e-qure.com

Number of Employees


Location

  • E-Qure Corp.
  • 20 West 64th Street
  • Suite 39G
  • New York
  • New York
  • 10023
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EQUROTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 1989

Biography

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimula ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 00:12
End of Day Share Price2019/08/09 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.